Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...
Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...
Eric Schmidt and other AI leaders (Karpathy, Musk, Anthropic executives) have described recursive self-improvement (RSI)—AI autonomously designing, testing, and deploying better versions of itself—as ...
Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the world in words, images, numbers and sounds (what I called WINS work in my ...
The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...
Abstract: This letter presents a novel method for environmental exploration that takes safety into account in unknown areas by using recursive Gaussian process regression (RGPR). Safety in unknown ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results